Tissue Regenix Group PLC Product launch in dCELL(R) division (8347I)
December 07 2022 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 8347I
Tissue Regenix Group PLC
07 December 2022
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
Product launch in dCELL (R) division
Launch of VNEW(R) Fascia Lata allograft used to address stress
urinary incontinence
Tissue Regenix (AIM: TRX), the regenerative medical device
company, announces the launch of VNEW(R) Fascia Lata allograft, an
additional line extension to the Company's dCELL(R) division .
The VNEW(R) Fascia Lata is a soft tissue allograft used to
support weakened tissue that can result in stress urinary
incontinence ('SUI'), which affects around one-third of adult women
at some point in their lives(1) . The number of women undergoing
surgery annually in the US for SUI is around 260,000(2) .
The VNEW(R) Fascia Lata allograft is manufactured under an
exclusive arrangement for ARMS Medical ('ARMS'), a partner with
which Tissue Regenix entered into a multi-year exclusive
distribution agreement (the 'Agreement') in 2018. The VNEW(R) brand
is owned by ARMS and consists of uniquely shaped products that
address pelvic health needs. The expansion of this Agreement with
ARMS adds VNEW(R) Fascia Lata to the exclusive distribution
portfolio of DermaPure(R) products to hospitals and surgeons
throughout the US for use in urology and gynaecology
procedures.
Daniel Lee, CEO of Tissue Regenix, commented: "Following the
successful launch of VNEW (R) with ARMS Medical in September 2021 ,
we are very pleased to be continuing our partnership and launching
the VNEW(R) Fascia Lata allograft for surgical procedures to
support tissue . The diversification of our product portfolio will
contribute to our market penetration, as well as provide a
significant improvement to quality of life for those patients that
receive these allografts."
Robert Greer, President & Founder of ARMS Medical, stated:
"We continue to be passionate about bringing innovative solutions
to market for women suffering from pelvic health issues. We are
excited about the launch of VNEW(R) Fascia Lata and credit our
strategic partner, Tissue Regenix, and our strong relationships
with best-in-class surgeons for making this a reality. Annually,
there are over a quarter million women who can benefit and improve
their quality of life with ARMS Medical's VNEW(R) solutions."
(1)
https://www.urologyhealth.org/urology-a-z/s/stress-urinary-incontinence-(sui)
(2) https://www.intechopen.com/chapters/80860
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Tel: +44(0)20 7710 7600
Adviser and Broker)
Ben Maddison / Nick Harland / Kate Hanshaw
Walbrook PR Ltd Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The Company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds, which enhance healing
opportunities of defects created by trauma and disease.
CellRight(R)'s human osteobiologics may be used in spine, trauma,
general orthopaedic, dental and ophthalmological surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PRLXQLLBLLLEFBD
(END) Dow Jones Newswires
December 07, 2022 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024